Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...

Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its Alzheimer's drug buntanetap. Read more here.

MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...

MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based ...

Annovis Bio’s buntanetap receives US patent for treatment and prevention of acute brain or nerve injuries: Malvern, Pennsylvania Thursday, January 16, 2025, 17:00 Hrs [IST] Anno ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for ...

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases with a market capitalization of $74 million, announced today that the U.S ...

Annovis Bio has a 1 year low of $4.21 and a 1 year high of $20.00. Annovis Bio ( NYSE:ANVS – Get Free Report ) last released its quarterly earnings results on Friday, November 8th.

Annovis Bio (NYSE:ANVS) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted an updated protocol for a pivotal Phase 3 trial for its Alzheimer's candidate, buntanetap.

(MENAFN- GlobeNewsWire - Nasdaq) MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug ...